According to a recent study published in JAMA Dermatology, which of the following factors do NOT contribute to treatment delay in melanoma? READ MORE
People who carry a BsmI single-nucleotide polymorphism are twice as likely to develop nonmelanoma skin cancer as their peers with similar known risk factors, such as older age, male sex, and light eye and skin color.
Men who use phosphodiesterase type 5 inhibitors have a slightly increased risk of developing melanoma and basal cell carcinoma.
Contrary to current guidelines, early melanoma patients under age 40 may be more suitable for sentinel lymph node biopsy than those over age 65.
Research in Review
Stage III and IV melanoma may have a profound impact on patients’ distress burden, which requires further intervention strategies.
The treatment of advanced melanoma represents a significant burden to the health system, and differs by insurance type and geographic location, according to the results of a regional analysis.
A combination of immunotherapy treatments improves survival and lowers the risk of life-threatening events for patients with late-stage melanoma compared with targeted therapy, according to a new JAMA Oncology report.